Akero ex­ec­u­tives point to ad­vanced fi­bro­sis pa­tients for MASH drug

Akero Ther­a­peu­tics ex­pects its promis­ing ex­per­i­men­tal MASH drug will be used to treat pa­tients with ad­vanced fi­bro­sis if it re­ceives FDA ap­proval, liken­ing MASH to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.